Bio Solution also gained on expectations surrounding its entry into China, one of the world’s largest osteoarthritis treatment markets. In contrast, Syntekabio fell sharply after its auditor issued a disclaimer of opinion.
|
Remedi shares rise on strong earnings
According to KG Zeroin’s MP Doctor, formerly MarketPoint, Remedi shares closed at 13,590 won, up 22.76% from the previous session. The rally was attributed to stronger-than-expected earnings.
Remedi posted consolidated revenue of 15.5 billion won ($11 million) and operating profit of 6.1 billion won in the first half of this year. First-half revenue alone surpassed the company’s full-year 2025 revenue of about 14.6 billion won, while operating profit was more than double last year’s annual operating profit of 2.8 billion won.
Remedi develops and commercializes X-ray systems based on proprietary technology that enables low radiation doses, high image quality and compact devices. Most of its sales come from its flagship REMEX-KA6, with overseas expansion driving growth.
The company has been rapidly increasing sales through a distribution network spanning more than 45 countries. Higher sales have also improved fixed-cost efficiency, helping Remedi achieve an operating margin approaching 40%.
Growth has been particularly strong in India. Last year, Remedi supplied portable X-ray systems to India’s National Tuberculosis Elimination Programme through the Central Medical Services Society, boosting its earnings. Last month, it was also selected as the only technically qualified bidder in a procurement tender by the Odisha state government, paving the way for expansion in India’s public procurement market.
Remedi plans to expand beyond India into other developing countries where tuberculosis remains a major public health problem.
“Tuberculosis itself is not necessarily a severe disease, but it can become extremely dangerous if left untreated,” a Remedi official said. “The disease tends to be concentrated in densely populated developing countries. X-ray screening is the only way to detect cases early enough to prevent further spread, and high-burden countries conduct mass screenings. We are therefore accelerating our expansion into those markets.”
Portability and price are key competitive strengths of the REMEX-KA6. The device weighs about 2.5 kilograms, roughly one-hundredth the weight of conventional 250-kilogram X-ray systems. It is also priced at about one-tenth the cost of conventional equipment.
“The REMEX-KA6 is highly portable, giving it a significant advantage in tuberculosis screening,” the official said. “It is also far less expensive than conventional systems, making it an attractive option for customers.”
Remedi is also acquiring a second manufacturing facility and introducing production automation to meet growing global demand. The company expects the additional capacity to support long-term growth.
“Our first-half results demonstrate that our proprietary technology and global distribution network are beginning to translate into tangible results,” the official said.
Bio Solution gains on China expansion
Bio Solution shares rose more than 19% during intraday trading before paring gains to close 8.7% higher at 7,250 won. The rally was attributed to expectations surrounding the company’s entry into China, which accounts for a significant portion of the global osteoarthritis treatment market.
According to Fortune Business Insights, China’s osteoarthritis therapeutics market was estimated at about $1 billion in 2025, equivalent to about 1.41 trillion won. That represents roughly 9.6% of the estimated $9.89 billion global market.
Bio Solution has opened a pathway into China for its osteoarthritis treatment CartiLife through the Hainan Free Trade Port’s special medical zone.
On Aug. 13, the company signed a partnership with Boao International Hospital, located in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan province, to introduce and administer CartiLife. The hospital treated its first patient in China on Aug. 14.
Boao International Hospital is a tertiary general hospital equipped with inpatient and outpatient facilities, an international regenerative medicine research center and a VIP rehabilitation and convalescence area, giving it infrastructure comparable to that of a midsize university hospital in South Korea.
Bio Solution’s China business is structured so that technology-fee revenue increases as the number of local CartiLife treatments rises. Earnings could therefore improve quickly if the company’s China business scales up.
The first treatment also marks the beginning of real-world data collection from Chinese patients. Bio Solution plans to continuously monitor treatment progress, safety and clinical outcomes to systematically build real-world evidence, or RWE, in China.
As of July 2, 2026, according to the Hainan Medical Products Administration, 27 drugs and medical devices had used RWE generated in Lecheng to support accelerated approval and market entry in China.
“We will strengthen operations across all areas, including local sales and marketing as well as manufacturing and quality management, so that CartiLife can establish itself as a competitive treatment option in China’s regenerative medicine market and translate into meaningful sales growth,” a Bio Solution official said.
Syntekabio tumbles after auditor disclaimer
Syntekabio plunged to its daily lower limit shortly after the market opened. The stock later recovered partially and closed at 1,131 won, down 24.45%. The decline followed an auditor’s disclaimer of opinion.
After the market closed Aug. 14, Syntekabio disclosed that its auditor, KPMG Samjong Accounting Corp., had issued a disclaimer of opinion on the company’s half-year financial report.
The auditor said it had been unable to obtain sufficient and appropriate audit evidence regarding the legitimacy of certain lending transactions and the use of the funds.
Syntekabio said the disclaimer stemmed from limitations related to audit procedures and supporting documentation. The company plans to work with outside specialists to review the reasons for the disclaimer and address the outstanding issues.
It has formed a team of legal and accounting advisers and begun preparing explanations and supplementary documentation.
Separately, Syntekabio said it will continue pursuing data center contracts and its artificial intelligence-based drug discovery platform business as part of efforts to normalize operations.
“We sincerely apologize for causing concern to shareholders and investors over the audit issue,” a Syntekabio official said. “We will resolve the audit-related matters quickly and transparently while doing our utmost to enhance shareholder value and normalize management based on the contracts and business results we have already secured.”
![[속보] 트럼프, 김정은 회동 추진…11월 APEC 가능성](https://image.edaily.co.kr/images/vision/files/NP/S/2026/08/PS26081900288t.jpg)
